"Analysis.group","Analysis.number","Analysis.name","Subgroup","Applicability","Study","Study.year","GIV.Mean","GIV.SE","Experimental.mean","Experimental.SD","Experimental.cases","Experimental.N","Control.mean","Control.SD","Control.cases","Control.N","O.E","Variance","Weight","Mean","CI.start","CI.end","Footnotes","review.url","review.doi","analysis_key","dataset_name","mismatch_type","direction_match","or_sig","rd_sig","log_or","rd","log_or_ci_lb","log_or_ci_ub","rd_ci_lb","rd_ci_ub","sparse_events","double_zero"
1,6,"Significant adverse events during maintenance therapy up to 6 months follow-up","Significant adverse events during maintenance therapy up to 6 months follow-up (all studies)","SUBGROUP_AND_OVERALL","Arshi 2021",2021,0,0,0,0,2,31,0,0,0,15,0,0,32.910929,2.5,0.127431,49.046027,NA,"https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013476.pub2/full","10.1002/14651858.CD013476.pub2","6::overall","CD013476_pub2_data","significance_only",TRUE,FALSE,TRUE,1.15108355855598,0.0811383195204096,-0.500908921819861,2.80307603893182,0.013517614831855,0.148759024208964,TRUE,TRUE
1,6,"Significant adverse events during maintenance therapy up to 6 months follow-up","Significant adverse events during maintenance therapy up to 6 months follow-up (all studies)","SUBGROUP_AND_OVERALL","Esmaeilzadeh 2015",2015,0,0,0,0,1,16,0,0,0,16,0,0,29.776479,3,0.131257,68.567734,NA,"https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013476.pub2/full","10.1002/14651858.CD013476.pub2","6::overall","CD013476_pub2_data","significance_only",TRUE,FALSE,TRUE,1.15108355855598,0.0811383195204096,-0.500908921819861,2.80307603893182,0.013517614831855,0.148759024208964,TRUE,TRUE
1,6,"Significant adverse events during maintenance therapy up to 6 months follow-up","Significant adverse events during maintenance therapy up to 6 months follow-up (all studies)","SUBGROUP_AND_OVERALL","Fruth 2013",2013,0,0,0,0,0,18,0,0,0,13,0,0,NA,NA,NA,NA,NA,"https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013476.pub2/full","10.1002/14651858.CD013476.pub2","6::overall","CD013476_pub2_data","significance_only",TRUE,FALSE,TRUE,1.15108355855598,0.0811383195204096,-0.500908921819861,2.80307603893182,0.013517614831855,0.148759024208964,TRUE,TRUE
1,6,"Significant adverse events during maintenance therapy up to 6 months follow-up","Significant adverse events during maintenance therapy up to 6 months follow-up (all studies)","SUBGROUP_AND_OVERALL","Świerczyńska-Krępa 2014",NA,0,0,0,0,4,12,0,0,0,8,0,0,37.312592,6.230769,0.380641,101.992341,NA,"https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013476.pub2/full","10.1002/14651858.CD013476.pub2","6::overall","CD013476_pub2_data","significance_only",TRUE,FALSE,TRUE,1.15108355855598,0.0811383195204096,-0.500908921819861,2.80307603893182,0.013517614831855,0.148759024208964,TRUE,TRUE
1,13,"Asthma exacerbations after 6 months follow-up","","SUBGROUP_AND_OVERALL","Esmaeilzadeh 2015",2015,0,0,0,0,4,16,0,0,8,16,0,0,45.157152,0.5,0.187659,1.332204,NA,"https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013476.pub2/full","10.1002/14651858.CD013476.pub2","13::overall","CD013476_pub2_data","significance_only",TRUE,FALSE,TRUE,-1.00319178267302,-0.228698593955469,-2.01040234467686,0.00401877933082884,-0.448599989325266,-0.00879719858567321,FALSE,FALSE
1,13,"Asthma exacerbations after 6 months follow-up","","SUBGROUP_AND_OVERALL","Mortazavi 2017",2017,0,0,0,0,5,19,0,0,9,19,0,0,54.842848,0.555556,0.228314,1.351829,NA,"https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013476.pub2/full","10.1002/14651858.CD013476.pub2","13::overall","CD013476_pub2_data","significance_only",TRUE,FALSE,TRUE,-1.00319178267302,-0.228698593955469,-2.01040234467686,0.00401877933082884,-0.448599989325266,-0.00879719858567321,FALSE,FALSE
